A Phase IB Study of BCL201 and Idelalisib in Patients with Recurrent or Persistent Follicular Lymphoma and Mantle Cell Lymphoma

Full Title

A Phase Ib Dose Escalation Study of BCL201 in Combination with Idelalisib in Patients with Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)


Idelalisib is a drug approved to treat chronic lymphocytic leukemia and follicular lymphoma that has come back despite prior therapy. In this study, researchers are finding the highest doses of idelalisib and an investigational drug called BCL201 that can be given together safely in patients with follicular lymphoma and mantle cell lymphoma that have come back or continued to grow despite treatment.

Both drugs target proteins involved in cancer cell growth. Idelalisib targets PI3 kinase and BCL201 targets Bcl-2. By interfering with the function of these proteins, researchers hope these two drugs will block some of the functions that cause cancer cells to grow and survive. Both idelalisib and BCL201 are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have follicular lymphoma or mantle cell lymphoma that has come back despite at least one but no more than four prior regimens of therapy.
  • At least 2 weeks must pass between completion of previous treatments and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Anas Younes at 212-639-5059.